Clinical Pulmonary Infection Score (CPIS) for VAP

Why use it

VAP is frequently over-diagnosed using clinical criteria alone (fever + leukocytosis + new infiltrate), leading to excessive antibiotic use. The CPIS provides a more structured and reproducible diagnostic framework, reduces unnecessary antibiotic prescribing in low-scoring patients, and can guide decisions about de-escalation of empirical therapy. A modified CPIS (with culture results) at 72 hours has been used in clinical trials to discontinue antibiotics when score falls below 6.

About

The Clinical Pulmonary Infection Score (CPIS) is a validated composite scoring system for the diagnosis of ventilator-associated pneumonia (VAP) in mechanically ventilated ICU patients. Originally proposed by Pugin et al. in 1991, it integrates clinical, physiological, radiographic, and microbiological parameters into a single score. VAP affects approximately 10–20% of mechanically ventilated patients and carries a mortality of 20–50%, making early and accurate diagnosis essential. The CPIS assigns weighted points to five or six domains (simplified vs. full version) and a score ≥6 is traditionally used as the diagnostic threshold. The score can be applied at the time of clinical suspicion (initial CPIS) or reassessed at 72 hours with culture results (modified CPIS).

When to use

• Clinical suspicion of VAP in any patient mechanically ventilated for ≥48 hours
• Evaluating a new fever, leukocytosis, or change in respiratory secretions in intubated ICU patients
• Guiding empirical antibiotic initiation in suspected VAP
• Reassessment at 72 hours with culture data to support antibiotic de-escalation or discontinuation
• Research classification of VAP in clinical trials (CPIS ≥6 as inclusion/exclusion criterion)

Formula

Pearls & pitfalls

• The simplified CPIS (items 1–5, max score 10) is used when culture results are pending — it is the most commonly used version at the bedside.
• A CPIS < 6 at 72 hours (full version with culture data) has been used in the Singh trial (NEJM 2000) to safely discontinue antibiotics in low-risk suspected VAP.
• The PaO2/FiO2 ratio cutoff of 240 mmHg identifies clinically significant oxygenation impairment; ARDS itself does not contribute additional points.
• Purulent secretions are the most subjectively assessed item — clinical assessment of color and consistency should be standardized between raters.
• The CPIS was not designed to differentiate VAP from HCAP or HAP — apply in mechanically ventilated patients only.
• ATS/IDSA 2016 guidelines note that CPIS alone has insufficient sensitivity and specificity to reliably diagnose VAP and should be used in conjunction with clinical judgment.
• New infiltrate must be present on CXR for VAP diagnosis — a pre-existing infiltrate worsening may qualify if CHF and ARDS are excluded.
• Microbiological confirmation (BAL ≥10⁴ CFU/mL or ETA ≥10⁵ CFU/mL) remains the diagnostic gold standard.

Next steps

CPIS < 6 (VAP unlikely): Consider alternative diagnoses (ARDS, pulmonary edema, atelectasis, pulmonary embolism). Withhold or discontinue empirical antibiotics if no other indication. CPIS ≥ 6 (VAP likely): Initiate empirical antibiotic therapy per local protocol targeting likely pathogens (Gram-negative bacilli including Pseudomonas in late-onset VAP; MRSA coverage if risk factors present). Obtain BAL or quantitative endotracheal aspirate culture. Reassess with modified CPIS at 72 hours using culture results.

Evidence

Pugin J et al. (Am Rev Respir Dis 1991) proposed CPIS in 28 patients. Singh N et al. (NEJM 2000) used CPIS <6 at 72h to discontinue antibiotics safely. Luna CM et al. (Chest 2003) validated CPIS in 69 VAP patients. Systemic reviews report sensitivity 65%, specificity 64% for CPIS ≥6. AUC approximately 0.68–0.78 across studies. Limited by interobserver variability in secretion and radiographic assessments.

References

1. Pugin J et al. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis. 1991;143(5):1121-1129. — link
2. Singh N et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000;162(2):505-511. — link
3. Kalil AC et al. Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the IDSA and ATS. Clin Infect Dis. 2016;63(5):e61-e111. — link